RMD Open

Article	Citations
Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial	162
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey	116
Reactive arthritis after COVID-19 infection	112
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme	98
Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases	78
Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey	74
Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review	74
Digital rheumatology in the era of COVID-19: results of a national patient and physician survey	73
Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study	62
Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin	58
Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases	56
Management of Fatigue in Rheumatoid Arthritis	53
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis	51
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study	50
Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rhe	48
Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis	47
Waiting for JAK inhibitor safety data	46
Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1)	45
Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients	44
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzer	43
High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry	43
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of	42
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who wer	41
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study	41
Peripheral spondyloarthritis: a neglected entity—state of the art	40

Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients	40
Part of pain labelled neuropathic in rheumatic disease might be rather nociplastic	39
Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA)	38
Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of diff	37
Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease	36
Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases	36
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry	35
Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis	35
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research	34
DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability	34
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?	33
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration	32
Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in p	32
Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR re	32
Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study	32
Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells	31
Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades	30
Depression and anxiety in an early rheumatoid arthritis inception cohort. associations with demographic, socioeconomic and disease features	30
Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic	30
Association between long-term exposure to air pollution and immune-mediated diseases: a population-based cohort study	30
Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with	30
All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015–2019	30
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure	30
CT-like images of the sacroiliac joint generated from MRI using susceptibility-weighted imaging (SWI) in patients with axial spondyloarthritis	30
Evidences for a protective role of vitamin D in COVID-19	29
Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients	28
Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study	27
To move or not to move: the paradoxical effect of physical exercise in axial spondyloarthritis	27
Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial	27
One in five patients with rapidly and persistently controlled early rheumatoid arthritis report poor well-being after 1 year of treatment	27
Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany	27
Is it Kawasaki shock syndrome, Kawasaki-like disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic	27
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes	27
Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies	26
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to tr	26
Impact of COVID-19 on vulnerable patients with rheumatic disease: results of a worldwide survey	26
Normal salivary gland ultrasonography could rule out the diagnosis of Sjögren’s syndrome in anti-SSA-negative patients with sicca syndrome	25
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension	25
Use of machine learning in osteoarthritis research: a systematic literature review	25
'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps	24
Role of synovial fibroblast subsets across synovial pathotypes in rheumatoid arthritis: a deconvolution analysis	24
Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines	23
Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis	23
The arthritis connection to inflammatory bowel disease (IBD): why has it taken so long to understand it?	23
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib	23
Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies	23
Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool	23
Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar	22
Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study	22
How to enhance recruitment of individuals at risk of rheumatoid arthritis into trials aimed at prevention: understanding the barriers and facilitators	22

Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era	22
Inflammaging as a link between autoimmunity and cardiovascular disease: the case of rheumatoid arthritis	22
TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD	21
Development and preliminary validation of the Behçet’s syndrome Overall Damage Index (BODI)	21
Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider	21
Effectiveness of remote care interventions: a systematic review informing the 2022 EULAR Points to Consider for remote care in rheumatic and musculoskeletal diseases	21
Effectiveness of self-management interventions in inflammatory arthritis: a systematic review informing the 2021 EULAR recommendations for the implementation of self-management strategies in patients	21
Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment	21
Application of the OMERACT Grey-scale Ultrasound Scoring System for salivary glands in a single-centre cohort of patients with suspected Sjögren’s syndrome	21
Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral	21
Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey	20
Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study	20
Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis f	20
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors	20
Patient’s experience of psoriatic arthritis: a conceptual model based on qualitative interviews	20
Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis	20
Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials	19
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phas	19
Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases	19
Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study—a randomised, double-blind, placebo-controlled, multicentre, investigator-initia	19
The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW	19
Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis	18
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study	18
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials	18
Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy	18
Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label exte	17
Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view	17
Gender equity in academic rheumatology: is there a gender gap at European rheumatology conferences?	17
Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases	17
Remote self-collection of capillary blood using upper arm devices for autoantibody analysis in patients with immune-mediated inflammatory rheumatic diseases	17
Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses	17
Comprehensive assessment of multimorbidity burden in a population-based cohort of patients with rheumatoid arthritis	17
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea	16
SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies	16
12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target	16
Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy	16
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension	16
Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL)	16
Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis	16
Health technology assessment: a framework	16
Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT	16
‘Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?’	16
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy	15
Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities	15
Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference	15
Vascular ultrasound for the diagnosis of giant cell arteritis: a reliability and agreement study based on a standardised training programme	15
A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studie	15
High body mass index is associated with increased risk for osteoarthritis of the first carpometacarpal joint during more than 30 years of follow-up	15
The wide range of opportunities for large language models such as ChatGPT in rheumatology	15
Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry	14
Impact of assessing patient-reported outcomes with mobile apps on patient–provider interaction	14
Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised co	14
Risk factors for venous thromboembolism and atherosclerotic cardiovascular disease: do they differ in patients with rheumatoid arthritis?	14
Development of classification criteria for hand osteoarthritis: comparative analyses of persons with and without hand osteoarthritis	14
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo	14
Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews	14
Association between social deprivation and disease activity in rheumatoid arthritis: a systematic literature review	14
Mixed results with baricitinib in biological-resistant adult-onset Still’s disease and undifferentiated systemic autoinflammatory disease	14
Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider	14
Autoantigen TRIM21/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren’s syndrome is associated with B cell hyperactivity and type I interferon a	14
Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry	14
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision	13
Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis	13
Association between T follicular helper cells and T peripheral helper cells with B-cell biomarkers and disease activity in primary Sjögren syndrome	13
Imaging in diagnosis, monitoring and outcome prediction of large vessel vasculitis: a systematic literature review and meta-analysis informing the 2023 update of the EULAR recommendations	13
Validation of a machine learning approach to estimate Systemic Lupus Erythematosus Disease Activity Index score categories and application in a real-world dataset	13
Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study	13
Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate	13
Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results	13
Effect of significant weight loss on disease activity: reason to implement this non-pharmaceutical intervention in daily clinical practice	13
Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis—going beyond treat to target	13
Lymphoma complicating rheumatoid arthritis: results from a French case–control study	13
Global, regional and national burdens of gout in the young population from 1990 to 2019: a population-based study	12
COVID-19-associated arthritis: an emerging new entity?	12
Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking	12
Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies	12
Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden	12
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy	12
Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy	12
High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis	12

Correction: High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV brasil registry	12
Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study	12
Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit	12
Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases	12
Fluorescence optical imaging: ready for prime time?	12
Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task force	12
Cost assessment of health interventions and diseases	12
Heterogeneity of axial spondyloarthritis: genetics, sex and structural damage matter	12
Direct oral anticoagulants versus vitamin K antagonists in patients with antiphospholipid syndrome: systematic review and meta-analysis	12
Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects	12
Spondyloarthritis in inflammatory bowel disease cohorts: systematic literature review and critical appraisal of study designs	12
Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination	12
Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis	12
Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMO	11
Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group	11
Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series	11
Performance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care	11
Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study	11
Assessment of competences in rheumatology training: results of a systematic literature review to inform EULAR points to consider	11
Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register	11
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study	11
Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses	11
Risk of psoriatic arthritis depending on age: analysis of data from 65 million people on statutory insurance in Germany	11
Health-related quality of life and disability in adults with juvenile idiopathic arthritis: comparison with adult-onset rheumatic diseases	11
Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus	11
Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis	11
Do you tweet?: trailing the connection between Altmetric and research impact!	11
Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observati	11
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III,	11
Effect of nurse-led care on outcomes in patients with ACPA/RF-positive rheumatoid arthritis with active disease undergoing treat-to-target: a multicentre randomised controlled trial	11
Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy	10
Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus	10
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3	10
Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry	10
Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients	10
Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)	10
What do patients prefer? A multinational, longitudinal, qualitative study on patient-preferred treatment outcomes in early rheumatoid arthritis	10
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis	10
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch fr	10
Effects of alcohol consumption and smoking on risk for RA: results from a Swedish prospective cohort study	10
Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials	10
Young people’s perspectives on patient-reported outcome measures in inflammatory arthritis: results of a multicentre European qualitative study from a EULAR task force	10
Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis	10
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison	10
Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease	10
What amount of structural damage defines sacroiliitis: a CT study	10
Prospective, simultaneous assessment of joint and vascular inflammation by PET/CT in tofacitinib-treated patients with rheumatoid arthritis: associations with vascular and bone status	10
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider	10
Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers	10
Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease	10
Premature coronary artery disease in patients with immune-mediated inflammatory disease: a population-based study	10
Neuropathic pain in the IMI-APPROACH knee osteoarthritis cohort: prevalence and phenotyping	10
ANCA-associated renal vasculitis is associated with rurality but not seasonality or deprivation in a complete national cohort study	10
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies	10
Temporomandibular disorders in patients with early rheumatoid arthritis and at-risk individuals in the Dutch population: a cross-sectional study	10
Strategies for the assessment of competences during rheumatology training across Europe: results of a qualitative study	9
Recurrence of axial spondyloarthritis among first-degree relatives in a prospective 35-year-follow-up family study	9
Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis	9
Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis	9
Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews i	9
Daratumumab for the treatment of refractory ANCA-associated vasculitis	9
Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial	9
Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations	9
Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry	9
Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry	9
Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension	9
Patient appropriateness for total knee arthroplasty and predicted probability of a good outcome	9
Cigarette smoking patterns preceding primary Sjögren’s syndrome	9
Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study	9
Role of vertebral corner inflammation and fat deposition on MRI on syndesmophyte development detected on whole spine low-dose CT scan in radiographic axial spondyloarthritis	9
Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis	9
Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?	9
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination	9
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider	9
Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial	9
Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares	9
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inf	9